About
Founded in 1965, Adimmune is the first in Taiwan to comply with GMP standards of the FDA and the EU
Adimmune Group
Enimmune
Upholding an idea that love is the starting point for everything meaningful, ENIMMUNE strives to take care of people through prevention and treatment. To protect people from diseases, we focus on the prevention and treatment of emerging infectious diseases in hopes of helping people live healthy and quality lives by facilitating the development of new drugs and vaccines.
WebsiteAnimmune
Since 2017, Adimmune and strategic investors start up new entity, Animmune, for animal vaccine development. Our mission is to find the solution for the unmet animal infectious disease via new technology. In the initial stage, Animmune synergize the well experience of the human vaccine technology, recombinant, Bacular-SF9-Insect-Cell system, and Adjuvant, from Adimmune and the innovative subunit vaccine platform from ATRI(Agricultural Technology Research Institute) to develop vaccines against PCV, SEP, HC.